News
Citing Indian Council for Medical Research (ICMR) and published studies, Dr Bhavesh Kotak, Head of Medical Affairs at Dr ...
Test positivity for common cold coronaviruses significantly declined following widespread SARS-CoV-2 infection and COVID-19 ...
12h
HealthDay on MSNCDC Now Recommends RSV Vaccine for Some Adults 50+The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV.
In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...
As many as 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine.
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they ...
FDA approval of Merck’s RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi’s Beyfortus. The new Merck product is expected to be discussed by the CDC’s Advisory Committee on ...
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...
The U.S. saw limited supply of antibody Beyfortus up to the 2023 RSV season, but the companies have since tripled production capacity and doubled the number of manufacturing sites.
US CDC Official in Charge of COVID, RSV Data Resigns Ahead of Vaccine Meeting By Julie Steenhuysen CHICAGO (Reuters) -A U.S. government scientist who oversees the team responsible for collecting ...
(RTTNews) - Moderna Inc. (MRNA) announced that the U.S. Food and Drug Administration has approved its respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345), for preventing lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results